Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
Should You Buy Ionis Pharmaceuticals (IONS) After Golden Cross?
10:56am, Thursday, 03'rd Jul 2025
After reaching an important support level, Ionis Pharmaceuticals, Inc. (IONS) could be a good stock pick from a technical perspective. IONS recently experienced a "golden cross" event, which saw its 5
Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last?
09:21am, Thursday, 03'rd Jul 2025
Ionis Pharmaceuticals (IONS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the
Ionis: After Years Of Investment, The Wholly-Owned Payoff Is In Sight
01:04pm, Sunday, 29'th Jun 2025
Ionis is transitioning from a licensing model to a commercial-stage biotech, investing heavily in its own drug launches and development pipeline. Upcoming catalysts include donidalorsen's FDA decision
Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
07:31am, Wednesday, 25'th Jun 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared positive topline results from the Phase 1 study of salanersen (ION306/BII
Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026
09:00am, Thursday, 12'th Jun 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Richard Geary, Ph.D., executive vice president and chief development officer, will retire effective J
First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome
07:00am, Wednesday, 11'th Jun 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the global Phase 3 REVEAL study, which is designed to evaluat
Why Is Ionis Pharmaceuticals (IONS) Up 5.5% Since Last Earnings Report?
12:37pm, Friday, 30'th May 2025
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?
Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study
10:01am, Tuesday, 20'th May 2025
Late-stage data shows that treatment with an 80mg dose of IONS' Tryngolza achieved a 61% placebo-adjusted reduction in triglyceride levels in six months.
Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides
07:00am, Monday, 19'th May 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the Essence study of olezarsen in people with moderate hypertriglyceridemia
Ionis to host 2025 virtual Annual Meeting of Stockholders
07:05am, Tuesday, 06'th May 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2025 virtual Annual Meeting of Stockholders followed by a general corpora
Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View
11:45am, Thursday, 01'st May 2025
IONS reports better-than-expected first-quarter results. The company raises its sales guidance for 2025 by more than 20% on the back of two new licensing deals.
Ionis Pharmaceuticals, Inc. (IONS) Q1 2025 Earnings Call Transcript
02:20pm, Wednesday, 30'th Apr 2025
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q1 2025 Earnings Conference Call April 30, 2025 11:30 AM ET Company Participants Wade Walke - SVP, IR Brett Monia - Founder, CEO & Director Kyle Jenne - EVP
Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge
02:05pm, Wednesday, 30'th Apr 2025
Ionis Pharmaceuticals Inc IONS reported a first-quarter EPS loss of 93 cents on Wednesday, down from a loss of 98 cents, beating the consensus of a $1.12 loss.
Ionis Pharmaceuticals (IONS) Reports Q1 Earnings: What Key Metrics Have to Say
10:35am, Wednesday, 30'th Apr 2025
Although the revenue and EPS for Ionis Pharmaceuticals (IONS) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare wit
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
09:20am, Wednesday, 30'th Apr 2025
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $0.98 per share a year ago.
